Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Biotechnology
|VRTX||Vertex Pharmaceuticals, Inc.||0.80%||212.06||1.9%||$521.91m|
|REGN||Regeneron Pharmaceuticals, Inc.||-1.77%||454.86||2.7%||$509.91m|
|GILD||Gilead Sciences, Inc.||0.88%||63.01||1.0%||$479.35m|
|ALXN||Alexion Pharmaceuticals, Inc.||-1.05%||150.37||2.0%||$354.39m|
|BNGO||Bionano Genomics, Inc.||-3.66%||9.48||0.0%||$340.06m|
|CRSP||CRISPR Therapeutics AG||-0.37%||129.77||0.6%||$302.39m|
|EXAS||EXACT Sciences Corp.||-2.72%||136.39||18.4%||$253.67m|
Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTORÂ®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.